Clinical Trial: Study of [212Pb]Pb-DOTAM-MAM279 in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

U.S., Dec. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07278479) titled 'Study of [212Pb]Pb-DOTAM-MAM279 in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors' on Nov. 10.

Brief Summary: The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [212Pb]Pb-DOTAM-MAM279, in patients aged >=18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: Large Cell Neuroendocrine Carcinoma Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC) Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) Small Cell Lung Cancer (SCLC) G...